Table 3 Overall objective response according to scheme of therapy
From: Acquired activated protein C resistance and thrombosis in multiple myeloma patients
Scheme | N | % |
|---|---|---|
VAD | 20 | 40 |
Overall objective response | 11/20 | 55 |
Thalidomide plus dexamethasone | 24 | 48 |
Overall objective response | 18/24 | 75 |
Melphalan plus prednisone | 6 | 12 |
Overall objective response | 2/6 | 33 |